ImmunoGen Announces Conference Call to Discuss Its 2018 Operating Results
January 24 2019 - 3:30PM
Business Wire
ImmunoGen, Inc., (Nasdaq: IMGN), a
leader in the expanding field of antibody-drug conjugates (ADCs)
for the treatment of cancer, today announced that the Company will
host a conference call at 8:00 a.m. ET on Friday,
February 8, 2019 to discuss its 2018 operating results.
Management will also provide a brief update on the business.
Conference Call InformationTo access the live call by
phone, dial 323-794-2093; the conference ID is 6271602. The call
may also be accessed through the Investors section of the Company’s
website, www.immunogen.com. Following the webcast, a replay of
the call will be available at the same location
through February 22, 2019.
ABOUT IMMUNOGENImmunoGen is developing the next
generation of antibody-drug conjugates (ADCs) to improve outcomes
for cancer patients. By generating targeted therapies with enhanced
anti-tumor activity and favorable tolerability profiles, we aim to
disrupt the progression of cancer and offer our patients more good
days. We call this our commitment to “target a better now.” Our
lead product candidate, mirvetuximab soravtansine, is in a Phase 3
study for folate receptor alpha (FRα)-positive platinum-resistant
ovarian cancer, and in Phase 1b/2 testing in combination regimens.
Our novel IGN candidates for hematologic malignancies, IMGN779 and
IMGN632, are in Phase 1 studies.
Learn more about who we are, what we do, and how we do it at
www.immunogen.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190124005187/en/
INVESTOR RELATIONS CONTACTSarah
Kiely781-895-0600sarah.kiely@immunogen.com
OR
THRUST Strategic CommunicationsChelcie
Lister910-777-3049chelcie@thrustsc.com
MEDIA CONTACTCourtney
O’Konek781-895-0600courtney.okonek@immunogen.com
OR
FTI ConsultingRobert
Stanislaro212-850-5657robert.stanislaro@fticonsulting.com
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Jun 2024 to Jul 2024
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Jul 2023 to Jul 2024